Higher S100B levels predict persistently elevated anhedonia with escitalopram monotherapy versus antidepressant combinations: Findings from CO-MED trial

Manish K Jha, Abu Minhajuddin, Bharathi Gadad, Cherise Chin Fatt, Madhukar H. Trivedi

Research output: Contribution to journalArticle

Abstract

Background: Elevated S100 calcium binding protein B (S100B) levels in systemic circulation may induce neuroinflammation and reflect greater blood–brain barrier (BBB) dysfunction. Neuroinflammation in patients with major depressive disorder (MDD), in turn, may reduce likelihood of improvement with serotonergic antidepressants. Methods: Levels of S100B were measured in plasma samples obtained prior to initiation of treatment with bupropion-plus-escitalopram, escitalopram-plus-placebo, or venlafaxine-plus-mirtazapine in participants of Combining Medications to Enhance Depression Outcomes trial (n = 153). Depression severity was measured with 16-item Quick Inventory of Depressive Symptomatology Self-Report and anhedonia was measured with 3 items of 30-item Inventory of Depressive Symptomatology. Differential changes in depression severity and anhedonia over acute-phase (baseline, weeks 1, 2, 4, 6, 8, 10, and 12) in the three treatment arms were tested with logS100B-by-treatment-arm interaction in mixed model analyses after controlling for age, gender, and body mass index. Results: There was a significant logS100B-by-treatment-arm interaction for anhedonia (F = 3.21; df = 2, 142; p = 0.04) but not for overall depression severity (F = 1.99; df = 2, 142; p = 0.14). Higher logS100B levels were associated with smaller reductions in anhedonia (effect size = 0.67, p = 0.047) in escitalopram monotherapy but not in the other two arms. Correlation coefficients of anhedonia severity averaged over acute-phase (including baseline) with baseline S100B levels were 0.57, −0.19, and 0.22 for escitalopram monotherapy, bupropion-plus-escitalopram and venlafaxine-plus-mirtazapine arms respectively. Conclusion: Higher baseline S100B levels in depressed patients resulted in poorer response to escitalopram monotherapy. Addition of bupropion, a dopaminergic antidepressant, partially mitigated this effect.

Original languageEnglish (US)
Article number184
JournalPharmaceuticals
Volume12
Issue number4
DOIs
StatePublished - Dec 2019

Keywords

  • Anhedonia
  • Antidepressant response
  • Blood
  • Brain barrier
  • Bupropion
  • Dopamine
  • Moderator
  • S100B
  • SSRIs
  • Serotonin

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Higher S100B levels predict persistently elevated anhedonia with escitalopram monotherapy versus antidepressant combinations: Findings from CO-MED trial'. Together they form a unique fingerprint.

  • Cite this